MET Exon 14 Deletion Analysis is performed by real-time RT-PCR. The assay is designed to detect alternative splice junctions that lead to exon-skipping (deletion) of exon 14 of the gene MET. Note: Available as stand-alone test or as part of the NeoTYPE® Lung Tumor Profile.
The MET (mesenchymal-epithelial transition) tyrosine kinase receptor and its ligand the hepatocyte growth factor (HGF) play a major role in oncogenesis in various types of cancers. MET amplification and mutations have been reported in various types of tumors, especially lung cancer. MET amplification or mutation can be primary or acquired after treatment with EGFR kinase inhibitors. The expression of a defective MET mRNA that skips exon 14 is recently reported in 4% of lung cancers. This finding is very important, because it is actionable. Dramatic response to MET/ALK inhibitors (crizotinib and cabozantinib) can be seen in patients with lung cancer and METex14 abnormality. Testing for METex14 is now considered by multiple clinical investigators as a standard of care in patients with lung cancer. MET exon 14 deletion is also seen in a subset of gastric and gastrointestinal carcinomas and gliomas.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transporting block during summer to prevent block from melting. Slides can be packed at room temperature.
14 days